SCHEMBL30869425

SCHEMBL30869425

CC(C)(C)OC(=O)N1C[C@H]2C[C@@H]1CN2CCN1c2ccc(Br)cc2Oc2cc(Br)cnc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.39
FGFR2 P21802 1/20 0.39
FGFR4 P22455 1/20 0.39
FGFR3 P22607 1/20 0.39
KDR P35968 1/20 0.39
GPR119 Q8TDV5 2/20 0.37
KCNK3 O14649 2/20 0.36
KCNK9 Q9NPC2 2/20 0.36
HSD11B1 P28845 1/20 0.35
GABRA1 P14867 2/20 0.35
GABRG2 P18507 2/20 0.35
GABRB3 P28472 2/20 0.35
GABRA5 P31644 2/20 0.35
GABRA3 P34903 2/20 0.35
GABRA2 P47869 2/20 0.35
GABRA6 Q16445 2/20 0.35
GABRB2 P47870 1/20 0.35
HDAC1 Q13547 1/20 0.34
RET P07949 2/20 0.34
SPR P35270 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30869634 1.00 FGFR1 (0.39) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869499 1.00 FGFR1 (0.39) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869448 0.90 HSD11B1 (0.40) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869789 0.90 FGFR1 (0.36) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869785 0.90 FGFR1 (0.36) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869913 0.90 FGFR1 (0.36) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869666 0.81 PIK3CD (0.41) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869591 0.81 PIK3CD (0.41) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869607 0.81 PIK3CD (0.41) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL30869558 0.80 UTS2R (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070880-A1 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES, INC. (US) 2026-03-12 US disclosed
EP-4583868-A2 DYNAMIN ACTIVATORS Walden Biosciences, Inc. (US) 2025-07-16 EP disclosed
WO-2024054661-A2 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES (US) 2024-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070880-A1 DYNAMIN ACTIVATORS DNM1, DNM1L, DNM2 FGFR1 1430/4885FGFR2 2027/4885FGFR4 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.